294 related articles for article (PubMed ID: 27386569)
1. Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer.
Singhal H; Greene ME; Tarulli G; Zarnke AL; Bourgo RJ; Laine M; Chang YF; Ma S; Dembo AG; Raj GV; Hickey TE; Tilley WD; Greene GL
Sci Adv; 2016 Jun; 2(6):e1501924. PubMed ID: 27386569
[TBL] [Abstract][Full Text] [Related]
2. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.
Kabos P; Finlay-Schultz J; Li C; Kline E; Finlayson C; Wisell J; Manuel CA; Edgerton SM; Harrell JC; Elias A; Sartorius CA
Breast Cancer Res Treat; 2012 Sep; 135(2):415-32. PubMed ID: 22821401
[TBL] [Abstract][Full Text] [Related]
3. Progestin-dependent induction of vascular endothelial growth factor in human breast cancer cells: preferential regulation by progesterone receptor B.
Wu J; Richer J; Horwitz KB; Hyder SM
Cancer Res; 2004 Mar; 64(6):2238-44. PubMed ID: 15026368
[TBL] [Abstract][Full Text] [Related]
4. Breast Cancer Suppression by Progesterone Receptors Is Mediated by Their Modulation of Estrogen Receptors and RNA Polymerase III.
Finlay-Schultz J; Gillen AE; Brechbuhl HM; Ivie JJ; Matthews SB; Jacobsen BM; Bentley DL; Kabos P; Sartorius CA
Cancer Res; 2017 Sep; 77(18):4934-4946. PubMed ID: 28729413
[TBL] [Abstract][Full Text] [Related]
5. Progesterone metabolites regulate induction, growth, and suppression of estrogen- and progesterone receptor-negative human breast cell tumors.
Wiebe JP; Zhang G; Welch I; Cadieux-Pitre HA
Breast Cancer Res; 2013 May; 15(3):R38. PubMed ID: 25927181
[TBL] [Abstract][Full Text] [Related]
6. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
7. ER-/PR+ breast cancer is controlled more effectively with an inflammatory inhibitor than hormonal inhibitor.
Song C; Kendi AT; Shim JY; Jung D; Kang PS; Lowe VJ; Lee S
Breast Cancer; 2023 May; 30(3):436-452. PubMed ID: 36859733
[TBL] [Abstract][Full Text] [Related]
8. Estrogen and progesterone receptors in the endometrium of postmenopausal breast cancer patients treated with tamoxifen and progestogens.
Cohen I; Altaras MM; Beyth Y; Shapira J; Figer A; Tepper R; Cordoba M; Yigal D; Bernheim J
Gynecol Oncol; 1997 Apr; 65(1):83-8. PubMed ID: 9103396
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of an estrogen receptor-regulated gene by first generation progestins requires both the progesterone receptor and estrogen receptor alpha.
Perkins MS; Louw-du Toit R; Jackson H; Simons M; Africander D
Front Endocrinol (Lausanne); 2022; 13():959396. PubMed ID: 36187129
[TBL] [Abstract][Full Text] [Related]
10. Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story.
McDaniel RE; Maximov PY; Jordan VC
Vitam Horm; 2013; 93():1-49. PubMed ID: 23810002
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype.
Schroth W; Winter S; Büttner F; Goletz S; Faißt S; Brinkmann F; Saladores P; Heidemann E; Ott G; Gerteis A; Alscher MD; Dippon J; Schwab M; Brauch H; Fritz P
Breast Cancer Res Treat; 2016 Jan; 155(1):85-97. PubMed ID: 26650824
[TBL] [Abstract][Full Text] [Related]
12. Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor.
Saji S; Omoto Y; Shimizu C; Warner M; Hayashi Y; Horiguchi S; Watanabe T; Hayashi S; Gustafsson JA; Toi M
Cancer Res; 2002 Sep; 62(17):4849-53. PubMed ID: 12208729
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression.
Knutson TP; Daniel AR; Fan D; Silverstein KA; Covington KR; Fuqua SA; Lange CA
Breast Cancer Res; 2012 Jun; 14(3):R95. PubMed ID: 22697792
[TBL] [Abstract][Full Text] [Related]
14. Additional value of the 70-gene signature and levels of ER and PR for the prediction of outcome in tamoxifen-treated ER-positive breast cancer.
Kok M; Koornstra RH; Mook S; Hauptmann M; Fles R; Jansen MP; Berns EM; Linn SC; Van 't Veer LJ
Breast; 2012 Dec; 21(6):769-78. PubMed ID: 22738860
[TBL] [Abstract][Full Text] [Related]
15. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
Cui X; Schiff R; Arpino G; Osborne CK; Lee AV
J Clin Oncol; 2005 Oct; 23(30):7721-35. PubMed ID: 16234531
[TBL] [Abstract][Full Text] [Related]
16. Progesterone induces progesterone receptor gene (PGR) expression via rapid activation of protein kinase pathways required for cooperative estrogen receptor alpha (ER) and progesterone receptor (PR) genomic action at ER/PR target genes.
Diep CH; Ahrendt H; Lange CA
Steroids; 2016 Oct; 114():48-58. PubMed ID: 27641443
[TBL] [Abstract][Full Text] [Related]
17. Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review.
Yeung C; Hilton J; Clemons M; Mazzarello S; Hutton B; Haggar F; Addison CL; Kuchuk I; Zhu X; Gelmon K; Arnaout A
Cancer Metastasis Rev; 2016 Sep; 35(3):427-37. PubMed ID: 27405651
[TBL] [Abstract][Full Text] [Related]
18. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
19. Progestin effects on breast cancer cell proliferation, proteases activation, and in vivo development of metastatic phenotype all depend on progesterone receptor capacity to activate cytoplasmic signaling pathways.
Carnevale RP; Proietti CJ; Salatino M; Urtreger A; Peluffo G; Edwards DP; Boonyaratanakornkit V; Charreau EH; Bal de Kier Joffé E; Schillaci R; Elizalde PV
Mol Endocrinol; 2007 Jun; 21(6):1335-58. PubMed ID: 17440047
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype.
Hefti MM; Hu R; Knoblauch NW; Collins LC; Haibe-Kains B; Tamimi RM; Beck AH
Breast Cancer Res; 2013; 15(4):R68. PubMed ID: 23971947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
